Undiagnosed Diseases Network

Undiagnosed Diseases Network
Name	Undiagnosed Diseases Network
Formation	2014
Type	Research consortium
Headquarters	United States
Leader title	Director

Undiagnosed Diseases Network The Undiagnosed Diseases Network is a United States-based consortium that connects clinical sites, research institutions, and diagnostic laboratories to investigate rare, unexplained medical conditions. Founded with support from federal agencies and academic partners, the Network integrates clinical genetics, genomics, and translational research to identify novel diagnoses, gene-disease relationships, and potential therapies. It collaborates with hospitals, universities, patient organizations, and funding agencies to accelerate rare disease discovery and patient care.

History

The Network was established in 2014 with initial support from the National Institutes of Health and the National Human Genome Research Institute, building on precedents set by the Human Genome Project and initiatives such as the Clinical Sequencing Exploratory Research programs. Early efforts drew on clinical models from institutions like Mayo Clinic, Johns Hopkins Hospital, and Boston Children's Hospital and research frameworks developed at Harvard Medical School and the Broad Institute. Over time the Network expanded through cooperative agreements similar to those used by the All of Us Research Program and incorporated methods from consortia including the International Rare Diseases Research Consortium and the Global Alliance for Genomics and Health. Leadership transitions reflected collaborations with academic centers such as University of California, San Francisco and Northwestern University.

Organization and Membership

Membership comprises clinical sites, sequencing centers, and biobank facilities affiliated with academic medical centers and research universities. Participating institutions have included clinical partners associated with Mayo Clinic, Washington University in St. Louis, Rady Children's Hospital, Vanderbilt University Medical Center, and Duke University School of Medicine. The Network coordinates with diagnostic laboratories at centers like the Baylor College of Medicine Human Genome Sequencing Center and the Columbia University Irving Medical Center genomic facilities. Governance includes scientific advisory boards with members tied to organizations such as the American Society of Human Genetics, the National Organization for Rare Disorders, and patient advocacy groups like Global Genes.

Mission and Activities

The Network’s mission emphasizes diagnosis, discovery, and dissemination: to provide answers to patients with unexplained conditions, to discover new gene-disease associations, and to share data and methods. Clinical activities mirror programs at tertiary referral centers such as Cleveland Clinic and Seattle Children's Hospital while research activities incorporate platforms used by the 100,000 Genomes Project and the Exome Aggregation Consortium. Outreach and education efforts align with patient advocacy work from groups like Rare Diseases Europe and foundations such as the Simons Foundation and the Chan Zuckerberg Initiative. The Network also engages with regulatory and policy stakeholders including the Food and Drug Administration and funding bodies such as the National Institute of Neurological Disorders and Stroke.

Research and Clinical Methods

The Network applies comprehensive phenotype-driven diagnostics combining deep clinical phenotyping, biochemical testing, and next-generation sequencing strategies used by centers such as the Wellcome Sanger Institute and the European Bioinformatics Institute. Methods include whole-exome sequencing, whole-genome sequencing, RNA sequencing, metabolomics, and functional assays modeled after work at the Max Planck Institute for Molecular Genetics and the Salk Institute for Biological Studies. Data sharing uses infrastructure and standards developed by the Global Alliance for Genomics and Health and repositories similar to the Database of Genotypes and Phenotypes. Collaborative analyses integrate tools from groups like the Broad Institute's Genome Analysis Toolkit and annotation resources from the Ensembl and UCSC Genome Browser teams. Multidisciplinary case review practices reflect approaches found in tertiary centers such as Stanford Medicine.

Notable Cases and Outcomes

The Network has reported diagnoses that elucidated novel gene-disease links and informed clinical management, echoing discoveries from institutions like Massachusetts General Hospital and diagnostic landmark cases from Children's Hospital of Philadelphia. Outcomes include identification of previously unrecognized metabolic disorders, neuromuscular syndromes, and syndromic presentations with actionable therapeutic implications, paralleling translational successes seen at the Institute of Genetics and Molecular Medicine and the Roberts Laboratory-style functional follow-ups. Case publications have appeared alongside reports from journals and consortia connected to Nature Genetics, The New England Journal of Medicine, and collaborative projects with groups like the Human Phenotype Ontology consortium.

Funding and Partnerships

Primary funding streams have included grants and cooperative agreements from the National Institutes of Health, with supplemental support from institutional funds at participating centers such as Yale School of Medicine and philanthropic contributions similar to those from the Bill & Melinda Gates Foundation and disease-specific foundations. Strategic partnerships involve collaborations with diagnostic service providers, biorepositories linked to the National Cancer Institute's repositories, and data-sharing alliances with initiatives such as the European Rare Disease Research Coordination. The Network also coordinates with policy and advocacy stakeholders including the Office of the Director of the National Institutes of Health and patient-led organizations like Genetic Alliance.

Category:Rare disease organizations